Evidence map›Paper›PMID 29973860›Full record

ArticleFrontiers in neuroscience2018

Estrogen Protects Neurotransmission Transcriptome During Status Epilepticus.

Dumitru A Iacobas, Sanda Iacobas, Nino Nebieridze, Libor Velíšek, Jana Velíšková

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Estrogen Receptors: A New Frontier in Alzheimer's Disease Therapy.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Article
  6. Role of Cholinergic Signaling in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Powerful quantifiers for cancer transcriptomics.World journal of clinical oncology · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Uncovering the Pharmacological Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2019
    Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dumitru A IacobasCenter for Computational Systems Biology, Prairie View A&M University, Prairie View, TX, United States.
Sanda IacobasCenter for Computational Systems Biology, Prairie View A&M University, Prairie View, TX, United States.
Nino NebieridzeDepartment of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, United States.
Libor VelíšekDepartment of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, United States.
Jana VelíškováDepartment of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, United States.
New York Medical College · USPrairie View A&M University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Women with epilepsy commonly have premature onset of menopause. The decrease in estrogen levels is associated with increased occurrence of neurodegenerative processes and cognitive decline. Previously, we found that estradiol (E2) replacement in ovariectomized (OVX) female rats significantly reduced the seizure-related damage in the sensitive hilar region of hippocampal dentate gyrus (DG). However, the complex mechanisms by which E2 empowers the genomic fabrics of neurotransmission to resist damaging effects of status epilepticus (SE) are still unclear. We determined the protective effects of the estradiol replacement against kainic acid-induced SE-associated transcriptomic alterations in the DG of OVX rats. Without E2 replacement, SE altered expression of 44% of the DG genes. SE affected all major functional pathways, including apoptosis (61%), Alzheimer's disease (47%), cell cycle (59%), long-term potentiation (62%), and depression (55%), as well as synaptic vesicle cycle (62%), glutamatergic (53%), GABAergic (49%), cholinergic (52%), dopaminergic (55%), and serotonergic (49%) neurotransmission. However, in rats with E2 replacement the percentage of significantly affected genes after SE was reduced to the average 11% (from 8% for apoptosis to 32% for GABAergic synapse). Interestingly, while SE down-regulated most of the synaptic receptor genes in oil-injected females it had little effect on these receptors after E2-replacement. Our novel Pathway Protection analysis indicated that the E2-replacement prevented SE-related damage from 50% for GABA to 75% for dopaminergic transmission. The 15% synergistic expression between genes involved in estrogen signaling (ESG) and neurotransmission explains why low E2 levels result in down-regulation of neurotransmission. Interestingly, in animals with E2-replacement, SE switched 131 synergistically expressed ESG-neurotransmission gene pairs into antagonistically expressed gene pairs. Thus, the ESG pathway acts like a buffer against SE-induced alteration of neurotransmission that may contribute to the E2-mediated maintenance of brain function after the SE injury in postmenopausal women. We also show that the long-term potentiation is lost in OVX rats following SE but not in those with E2 replacement. The electrophysiological findings in OVX female rats with SE are corroborated by the high percentage of long-term potentiation regulated genes (62%) in oil-injected while only 13% of genes were regulated following SE in E2-replaced rats.

Indexed as

beta-estradiolcholinergic synapsedentate gyrusdopaminergic synapseGABAergic synapseglutamatergic synapsejun oncogeneserotonergic synapse

Identifiers

PMID29973860
PMCPMC6019481
OpenAlexW2809038362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.